Deciphera Pharms Drug Patent Portfolio
Deciphera Pharms owns 1 orange book drug protected by 36 US patents Given below is the list of Deciphera Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11779572 | Methods of treating gastrointestinal stromal tumors | 06 Oct, 2042 | Active |
| US11969414 | Methods of treating gastrointestinal stromal tumors | 08 Feb, 2041 | Active |
| US11185535 | Amorphous kinase inhibitor formulations and methods of use thereof | 30 Dec, 2040 | Active |
| US11395818 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11576903 | Amorphous kinase inhibitor formulations and methods of use thereof | 30 Dec, 2040 | Active |
| US11612591 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11793795 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11801237 | Amorphous kinase inhibitor formulations and methods of use thereof | 30 Dec, 2040 | Active |
| US11844788 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11850240 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11850241 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11896585 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11903933 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11911370 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11918564 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US11969415 | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US12023328 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US12064422 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea | 30 Dec, 2040 | Active |
| US10966966 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11266635 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11344536 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11426390 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11433056 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11529336 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11534432 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11576904 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US11813251 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US12023325 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US12023326 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US12023327 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US12059410 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US12059411 | Methods of treating gastrointestinal stromal tumors | 12 Aug, 2040 | Active |
| US8461179 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | 15 May, 2034 | Active |
| US8940756 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | 07 Jun, 2032 | Active |
| USRE48731 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | 07 Jun, 2032 | Active |
| US8188113 | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | 27 Jul, 2030 | Active |
Latest Legal Activities on Deciphera Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Deciphera Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11918564 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11779572 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11850241 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11911370 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11969415 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11969414 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11844788 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11850240 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11896585 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11903933 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11813251 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11793795 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 03 Jul, 2024 | US11801237 |
|
Electronic Review
Critical
| 07 Jun, 2024 | US11969414 |
|
Email Notification
Critical
| 30 Apr, 2024 | US11969414 |
Deciphera Pharms's Family Patents
Deciphera Pharms drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 44.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Deciphera Pharms Drug List
Given below is the complete list of Deciphera Pharms's drugs and the patents protecting them.
1. Qinlock
Qinlock is protected by 36 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11779572 | Methods of treating gastrointestinal stromal tumors |
06 Oct, 2042
(17 years from now)
| Active |
| US11969414 | Methods of treating gastrointestinal stromal tumors |
08 Feb, 2041
(16 years from now)
| Active |
| US11185535 | Amorphous kinase inhibitor formulations and methods of use thereof |
30 Dec, 2040
(16 years from now)
| Active |
| US11395818 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11576903 | Amorphous kinase inhibitor formulations and methods of use thereof |
30 Dec, 2040
(16 years from now)
| Active |
| US11612591 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11793795 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11801237 | Amorphous kinase inhibitor formulations and methods of use thereof |
30 Dec, 2040
(16 years from now)
| Active |
| US11844788 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11850240 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11850241 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11896585 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11903933 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11911370 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11918564 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US11969415 | (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US12023328 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US12064422 | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea |
30 Dec, 2040
(16 years from now)
| Active |
| US10966966 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11266635 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11344536 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11426390 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11433056 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11529336 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11534432 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11576904 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US11813251 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US12023325 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US12023326 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US12023327 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US12059410 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US12059411 | Methods of treating gastrointestinal stromal tumors |
12 Aug, 2040
(15 years from now)
| Active |
| US8461179 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
15 May, 2034
(9 years from now)
| Active |
| US8940756 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
07 Jun, 2032
(7 years from now)
| Active |
| USRE48731 | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
07 Jun, 2032
(7 years from now)
| Active |
| US8188113 | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
27 Jul, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qinlock's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List